The 2014 format is similar to last year and includes a single schedule for persons 0 through 18 years of age (Fig 1) . The yellow bars indicate the recommended age range for all children and contain a notation indicating the recommended dose number by age. The green bars indicate the recommended catch-up age. The purple bars designate the range for immunization for certain groups at high risk. The combined green and purple bar indicates the recommended age when hepatitis A vaccine catch-up is recommended. The white boxes show the ages when a vaccine is not recommended routinely. The catch-up schedule offers recommendations for children and adolescents who start late or are >1 month behind (Fig 2) .
Footnotes contain recommendations for routine vaccination, for catchup vaccination, and for vaccination of children and adolescents with high-risk conditions or in special circumstances. Numerous changes have been made to improve the clarity and readability of the footnotes. A parent-friendly vaccine schedule for children and adolescents is available at http://www.cdc.gov/vaccines/schedules/index.html. An adult immunization schedule also is published in February of each year and is available at www.cdc.gov/vaccines. These schedules are revised annually to reflect current recommendations for the use of vaccines licensed by the US Food and Drug Administration and include the following specific changes from last year:
Both generic names and trade names are referenced in the title of each vaccine footnote; thereafter, only the trade name is used, as in the rotavirus footnote.
The Tdap footnote includes information on vaccination of persons 7 years and older with a single lifetime dose of Tdap, except for pregnant adolescents, who should be vaccinated with each pregnancy. For pregnant adolescents, administration is preferred during week 27 through week 36 of gestation, regardless of time since previous Td or Tdap.
The Haemophilus influenzae type b footnote clarifies vaccination of children 12 through 59 months of age who are at increased risk because of incomplete vaccination, asplenia, HIV infection, receipt of hematopoietic stem cell transplant, or receipt of chemotherapy or radiation treatment.
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The pneumococcal vaccine footnote itemizes recommendations for PCV13 and PPSV23 use in children and adolescents at increased risk on the basis of age and degree of risk.
The influenza vaccine footnote describes vaccine dosing for children 6 months through 8 years of age and for those 9 years of age and older for the 2013-2014 season.
The hepatitis A vaccine footnote includes the list of persons at increased risk of hepatitis A disease. . Please note that the following corrections have been made to the electronic version available at http://pediatrics.aappublications.org/content/133/2/ 357.full?sid5a26ca8bf-796e-47a4-82e8-35775f90c3a5 and that these corrections should be made to the version that appeared in the printed journal.
In Fig 1 (0-18 yrs schedule) , in the first box for Tetanus, diphtheria, & acellular pertussis, the parentheses should read: (Tdap ‡7 yrs)
In Fig 1 (0-18 yrs schedule) , in the first box for Meningococcal, the paren- Table) to differentiate clearly the 21 independent signs. 
